# Topotarget A/S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/topotarget-a-s

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.topotarget.com
- Total disclosed funding: $19M
- Latest round: Series C (Mar 22, 2005)
- Investors on record: 3

## About

Topotarget A/S is a Danish biopharmaceutical company engaged in the development of innovative therapies, primarily focusing on oncology and related diseases, with a strategic intent towards advancing its product offerings.Topotarget A/S was founded in 2000 and is headquartered in Copenhagen, Denmark. The company specializes in the development of biopharmaceuticals aimed at treating cancer. In June 2005, Topotarget successfully completed an IPO, raising DKK 225 million by issuing 10 million shares at DKK 22.50 each. In April 2014, Topotarget entered into a merger agreement with BioAlliance Pharma, with the financial terms undisclosed and expected completion by August 2014. The firm has completed a total of 3 deals since its inception.Topotarget.com is positioned as a domain name available for sale, with no active products or services currently offered by the owner. The domain serves primarily as a resource for potential investors or companies aiming to utilize the Topotarget name for their own branding and digital strategy. There is no defined client base as it is primarily marketed as a digital asset, appealing to a global audience interested in establishing a digital presence.In 2013, Topotarget reported a revenue of DKK 1,484,164 and an EBITDA of DKK -5,747,086. Currently, the domain Topotarget.com is listed for sale with an asking price of USD 3,825, relying on the successful sale to generate revenue.Following the completion of the IPO in June 2005, which raised DKK 225 million, and the merger with BioAlliance Pharma in April 2014, Topotarget A/S is focused on integrating its operations and enhancing its portfolio. The strategic growth plan includes launching new products and expanding into new markets. The merger is expected to broaden its reach and capabilities in the oncology space. Specific details regarding upcoming product launches and geographic expansions have not been disclosed, but there are aspirations to leverage the synergies from the merger to bolster market presence.

## Funding rounds

- Series C, Mar 22, 2005, $19M — HealthCap, Deutsche Venture Capital, BankInvest

## Investors

- HealthCap — Series C
- Deutsche Venture Capital (https://capitalatlas.ai/funds/deutsche-venture-capital) — Series C
- BankInvest (https://capitalatlas.ai/funds/bankinvest) — Series C